



ACURATE *neo*[™] Aortic Valve System

Length of Stay with ACURATE *neo* vs. Evolut[™] R

Routine use of the ACURATE *neo* self-expanding valve is associated with improved procedural outcomes and reduced post-operative length of stay: Insights from a single-center registry (ACURATE *neo* vs. Evolut R)

Kotronias RA, Banning AP, Kharbanda RK. Oxford University Hospital. Presented at EuroPCR 2019 by R. A. Kotronias.

Study Design

Single-center study from Oxford, Great Britain, evaluating the impact of valve selection on procedural outcomes, length of stay (LoS), and 30-day mortality in 231 patients treated with either ACURATE *neo* (n = 143) or Evolut R (n = 88) between March 2017 and September 2018.


Clinical Highlights

ACURATE *neo* demonstrates reduced post-operative complications and permanent pacemaker rates and comparable mortality and stroke rates vs. Evolut R.


Improvements in procedural outcomes with ACURATE *neo* are associated with reductions in post-operative length of stay

A multivariate linear regression model identified peri-procedural complications, pre-existing RBBB, and new permanent pacemaker implantation as independent predictors of post-operative length of stay.

Procedural Outcomes



Post-Operative Length of Stay



All trademarks are the property of their respective owners.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Not intended for use or distribution in France, Japan, and the USA.
SH-655603-AA

Boston Scientific
 Advancing science for life™

www.bostonscientific.eu/ACURATEno
 © 2019 Boston Scientific Corporation
 or its affiliates. All rights reserved.
 DINSH0243EA